Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in the U.S. and Canada

Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in
                             the U.S. and Canada

Expansion Completes Galderma's Global Skin Health Footprint

PR Newswire

FORT WORTH, Texas, July 10, 2014

FORT WORTH, Texas, July 10, 2014 /PRNewswire/ --Galderma S.A. (Galderma)
announced that it has gained full rights to distribute Restylane®, Perlane®,
Emervel®, Sculptra® and Dysport® from Valeant Pharmaceuticals International,
Inc. The expansion into aesthetic and corrective dermatology in the U.S. and
Canada completes Galderma's global skin health footprint and extends its
leadership in aesthetic medicine worldwide.

"We at Galderma are delighted to bring Restylane®, Perlane®, Emervel®, and
Dysport® home in the U.S. and Canada as is the case in dozens of countries
around the world. Adding Sculptra® to our global portfolio allows us to bring
additional indications to our broad range of medical solutions for people with
skin needs," said Humberto C. Antunes, CEO and President of Galderma
worldwide. "Our science-based approach to fillers and muscle relaxants takes
our solutions beyond the aesthetic level to an integral part of holistic
medicine, where maintaining, preserving and restoring the health of the skin
is as important and as relevant as treating or correcting conditions. With
Restylane, Perlane, and Dysport, as well as the innovations to come, we
complement our line of prescription and self-medication products to give
physicians an arsenal of effective solutions," added Antunes. 

Two of Galderma's most recent innovations in the field, Emervel® Classic and
Emervel® Deep, have been submitted for approval by the FDA and Health Canada
and are currently under review.

"The U.S. and Canada represent more than 50 percent of the fast growing global
medical aesthetics markets," said Stuart Raetzman, Vice President of Galderma
for North America. "Demographics, social and cultural drivers, as well as an
improving economy, make this an ideal time for Galderma to expand its
geographic footprint in aesthetic and corrective medicine to the United States
and Canada. At Galderma, people come first. We are thrilled to take on board
the experienced teams from Valeant Aesthetics and, more than ever, our intent
is to preserve the quality of the long-lasting relationships built with
doctors. We look forward to partnering with healthcare providers in the growth
and expansion of aesthetic and corrective medicine in North America and
advancing the care and treatment of patients."

Galderma will pursue to distribute the acquired products through the existing
distribution partner. Healthcare practitioners are invited to continue to
order products through their current account number and phone numbers.
Beginning July 28, Galderma will have a new branded distribution process. All
accounts will automatically receive a new Galderma account number and
information on the new ordering process.

"This agreement reinforces Galderma's long-term commitment to meet physician
and patient needs worldwide. Our high level of investment in Research &
Development allows us to continue to develop new products and to bring
innovation with the highest standards of clinical safety and efficacy," added
Antunes. "This expansion demonstrates Galderma's sole focus on dermatology and
skin health and its ongoing dedication to research and innovation."

About Restylane & Perlane

The Restylane family of products includes Restylane, Restylane‐L, Perlane, and
Perlane‐L. These productscan be used to correct moderate to severe facial
wrinkles and folds, such as the lines from the nose tothe corners of the
mouth (nasolabial folds), by adding volume and fullness to the skin. Restylane
andRestylane‐L may also be used for lip enhancement in patients over
21.These products have now been used in over 20 million facial aesthetic
treatments in more than 65countries worldwide, with a safety and efficacy
profile supported by scientific research, clinical studiesand extensive
clinical experience, including over 30 scientific publications based on
randomizedcontrolled trials.

About Emervel

Emervel, an innovative, next generation family of hyaluronic acid soft dermal
fillers, is specificallydesigned to enhance patient tolerability and provide
long‐lasting correction of facial lines, contouringand volume loss or lip
enhancement. Emervel was launched in Europe in 2010. Emervel Classic
andEmervel Deep have been submitted to the FDA and regulatory activities to
support approval are ongoing.

About Dysport

Dysport (botulinum toxin A) is a prescription injection with an aesthetic
indication for temporary improvement in the appearance of moderate to severe
glabellar lines associated with procerus and corrugator muscle activity in
adults under 65. Dysport was first approved for use outside the U.S. in 1991.
It is available today for aesthetic use in 57countries and has been approved
for aesthetic use in the U.S. since 2009.

About Sculptra

Sculptra® (Poly‐L‐lactic acid (PLLA)) was approved for use in Europe in 1999.
In the United States, it wasapproved by the Food and Drug Administration in
2004 for the treatment of facial lipoatrophyassociated with human
immunodeficiency virus (HIV), and in 2009 for cosmetic indications in
immune-competentpatients. Sculptra Aesthetic is a unique treatment option in
the world of Medical Aesthetic treatments that allowsclinicians to work
directly with the patient to help replace lost collagen, through a series of
treatments.On average, three injection sessions are required over a period of
a few months. The number of injection sessions and the number of injections
per session vary from person to person with clinicalresults persisting up to
25 months.

About Galderma

Galderma is a global company founded in 1981 committed to delivering
innovative medical solutions tomeet the dermatological needs of people
throughout their lifetime while serving healthcareprofessionals around the
world. The company has 34 wholly owned affiliates with a worldwide networkof
distributors and more than 5,000 employees. Galderma's extensive product
portfolio is available in 80countries and treats a range of dermatological
conditions including: acne, rosacea, onychomycosis, psoriasis &
steroid‐responsive dermatoses, pigmentary disorders, skin cancer and medical
solutions forskin senescence. With approximately 19% of revenues invested
each year to discover and develop newproducts and access innovative
technologies, the company is one of the world's leading investors
indermatology R&D. Five state‐of‐the‐art R&D centers and five manufacturing
sites are dedicated toproviding a wide range of innovative medical solutions
which meet the highest standards of safety and efficacy. Strategic brands
include Epiduo, Oracea, Clobex, Differin, Mirvaso,
Rozex/MetroGel,Silkis/Vectical, Tri‐Luma, Loceryl, Cetaphil, Nutraderm,
Nutraplus, Metvix, Azzalure/Dysport, Restylaneand Emervel.

SOURCE Galderma S.A.

Contact: Galderma Laboratories, L.P., Virginie Naigeon, Director of Public
Relations and Internal Communications, U.S., Communications - Galderma North
America,, office: 817 961 5014; or Margulies
Communications Group, Jamie, office: 214?368?0909;
cell: 469?867?7289
Press spacebar to pause and continue. Press esc to stop.